Economics and mental health are intertwined. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Caring for elderly people with dementia is associated with well-documented increases in burden, distress, and decrements in mental health and wellbeing. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Divorced marital status was significantly associated with an increased LOS following TKA. 5 key findings →
Participants: 234 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Our findings suggest that non-economic social deprivation, especially in terms of access to a grocery store, pharmacy, postal office, and bus stop, might be relevant for maintaining cognitive functioning in old age. 4 key findings →
Design: longitudinal study Participants: 91 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
TBI had the highest percentage (37%) compared to other conditions, which may be attributed to the prevalent challenge of cognitive impairment in TBI in addition to physical disability. 5 key findings →
Design: cohort study Participants: 2,285 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
48/100
In 2014 and 2016, the overall prevalence of AD/ADRD diagnoses was 5.6% and 6.5%, respectively. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The newly diagnosed ADRD and new AChEI users cohorts included 861,727 and 395,319 patients, respectively. 5 key findings →
Design: cohort study Participants: 861,727 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Prior authorization criteria for Federal Drug Administration (FDA) approved immunotherapeutics, among the class of anti-amyloid monoclonal antibodies (mAbs), established by state drug formulary committees, are tailored for adults with late-onset Alzheimer's disease. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
48/100
Among 52 participants recruited, 27 were former caregivers, 16 were current caregivers, and nine were persons with dementia; experiences reflected Alzheimer's (n = 18), sporadic Creutzfeldt-Jakob (n = 12), Lewy body (n = 7), and other dementias (n = 15). 5 key findings →
Participants: 18 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia is a leading global cause of morbidity and mortality. 2 key findings →
Participants: 15 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Many studies have examined factors associated with individuals of high or low healthcare spending in a given year. 5 key findings →
Design: longitudinal study Participants: 30,729 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Additionally, it is unknown whether the benefits of this cap would vary between Medicare patients with type 1 versus type 2 diabetes. 4 key findings →
Design: cross-sectional Participants: 2,227,229 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
48/100
Older adults with sensory and cognitive impairments constitute a particularly prevalent and vulnerable population who are at increased risk of hospitalization and contribute to higher healthcare spending. 5 key findings →
Participants: 24 Evidence: low
Full summary, score breakdown and related studies → Original source
Dual hospice/SNF access may result in fewer hospital deaths and higher quality of life for dying NH residents. 3 key findings →
Participants: 99,370 Evidence: low
Full summary, score breakdown and related studies → Original source
Medicare expenditures among nursing home residents with advanced dementia vary substantially. 4 key findings →
Participants: 323 Evidence: low
Full summary, score breakdown and related studies → Original source
Parkinson's disease (PD), following Alzheimer's disease, is the second-most common neurodegenerative disorder in the United States. 5 key findings →
Participants: 630,000 Evidence: low
Full summary, score breakdown and related studies → Original source
Although persons with dementia are frequently hospitalized, relatively little is known about the health profile, patterns of health care use, and mortality rates for patients with dementia who access care in the emergency department (ED). 4 key findings →
Participants: 10,354 Evidence: low
Full summary, score breakdown and related studies → Original source
Assisted-living facilities (ALFs), which provide a community for residents who require assistance throughout their day, are an important part of the long-term-care system in the United States. 5 key findings →
Participants: 32 Evidence: low
Full summary, score breakdown and related studies → Original source
We identified a cohort of 3619 incident dementia cases, 38.9% were male, and 66.9% were non-Hispanic White. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
This cross-sectional study examines upper bound and lower bound annualized Medicare costs for administering aducanumab to beneficiaries with the approved indications of mild cognitive impairment or mild dementia. 1 key finding →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
The average cost per enrollee per month was $110, or $1,320 per annum. 5 key findings →
Participants: 360 Evidence: low
Full summary, score breakdown and related studies → Original source
In both databases, total healthcare resource utilization and costs increased with number of core features. 4 key findings →
Participants: 536 Evidence: low
Full summary, score breakdown and related studies → Original source
On average, ADRD diagnosis was not significantly associated with excess Medicare payments over the last 5 years of life. 5 key findings →
Participants: 4,899 Evidence: low
Full summary, score breakdown and related studies → Original source
Most PWD (67%) met criteria for another manifestation of serious illness (24% advanced medical condition, 44% ADL impairment). 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
This global study estimated how much dementia costs the world, combining formal healthcare spending with the value of unpaid family caregiving across 204 countries. 4 key findings →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source
From across this tag
9 of the 705 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
- Patient cognitive impairment associated with higher home health care delivery costs
- Advance care planning among Medicare beneficiaries with dementia undergoing surgery
- Should I stay or should I go again: Multiple switching between fee‐for‐service Medicare and Medicare advantage among older beneficiaries
- The global macroeconomic burden of Alzheimer's disease and other dementias: estimates and projections for 152 countries or territories
- Cost-consequence analysis of the partner in balance program for informal carers of persons with dementia
- Cost-Effectiveness of Donanemab for Early Alzheimer Disease in Australia
- Regulation of Gut Microbiota and Metabolic Endotoxemia with Dietary Factors
- Increased risk for dementia in neurofibromatosis type 1
- Equity and budget challenges associated with the employment of anti-amyloid monoclonal antibodies for early Alzheimer's Disease in Italy: A scenario analysis
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →